The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
Settlement overview. On 3 Aug 2025 Chemours, DuPont and Corteva entered a proposed Judicial Consent Order with New Jersey that would resolve all state PFAS and legacy-site contamination claims. The Companies will pay an aggregate $875 million in cash to the state, spread over 25 years starting no earlier than 1 Jan 2026; the total present value, discounted at 8%, is about $500 million. Chemours will fund 50%, DuPont 35.5% and Corteva 14.5%.
Funding & security. Site-specific Remediation Funding Sources will be backed by surety bonds, and DuPont/Corteva will establish a separate Reserve Fund (71%/29%) for future remediation. A parallel Insurance Proceeds MOU lets DuPont and Corteva purchase Chemours’ rights to $150 million of potential PFAS insurance recoveries; after repayment plus a fee, further proceeds are split 50/50. Chemours expects existing escrowed cash and the assigned insurance proceeds to cover its settlement payments through at least 2030.
Next steps & impact. The deal needs public notice, comment and court approval and contains no admission of liability. It reduces legal uncertainty and staggers cash outflows, but long-term PFAS exposure, possible additional remediation costs and regulatory shifts remain key risks, as outlined in the forward-looking-statement section.